178 related articles for article (PubMed ID: 31775762)
1. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin.
Martin ML; Bitzer AA; Schrader A; Bergmann-Leitner ES; Soto K; Zou X; Beck Z; Matyas GR; Dutta S
Malar J; 2019 Nov; 18(1):377. PubMed ID: 31775762
[TBL] [Abstract][Full Text] [Related]
2. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
[TBL] [Abstract][Full Text] [Related]
3. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
4. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.
Hutter JN; Robben PM; Lee C; Hamer M; Moon JE; Merino K; Zhu L; Galli H; Quinn X; Brown DR; Duncan E; Bolton J; Zou X; Angov E; Lanar DE; Rao M; Matyas GR; Beck Z; Bergmann-Leitner E; Soisson LA; Waters NC; Ngauy V; Regules J; Dutta S
Vaccine; 2022 Sep; 40(40):5781-5790. PubMed ID: 36055874
[TBL] [Abstract][Full Text] [Related]
5. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
[TBL] [Abstract][Full Text] [Related]
6. Optimization of a
Langowski MD; Khan FA; Bitzer AA; Genito CJ; Schrader AJ; Martin ML; Soto K; Zou X; Hadiwidjojo S; Beck Z; Matyas GR; Livingstone MC; Batchelor AH; Dutta S
Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3114-3122. PubMed ID: 31988134
[No Abstract] [Full Text] [Related]
7. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
[TBL] [Abstract][Full Text] [Related]
8. Live attenuated rubella vectors expressing Plasmodium falciparum circumsporozoite protein (Pf-CSP) provide a novel malaria vaccine platform in the rhesus macaque.
Virnik K; Zhou W; Medvedev A; Walsh G; Perry-Anderson J; Majam V; Felber BK; Kumar S; Berkower I
Biochem Biophys Res Commun; 2021 Nov; 577():58-63. PubMed ID: 34507066
[TBL] [Abstract][Full Text] [Related]
9. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
Front Immunol; 2021; 12():641421. PubMed ID: 33815393
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
11. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.
Stahl-Hennig C; Suh YS; Park KS; Sauermann U; Kim KS; Ahn S; Franz M; Schulte R; Stolte-Leeb N; Hunsmann G; Sung YC
J Med Primatol; 2007 Aug; 36(4-5):195-205. PubMed ID: 17669208
[TBL] [Abstract][Full Text] [Related]
15. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
[TBL] [Abstract][Full Text] [Related]
17. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
[TBL] [Abstract][Full Text] [Related]
19. Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
Shears MJ; Watson FN; Stone BC; Cruz Talavera I; Parthiban C; Matsubara J; Kc N; Sim BKL; Hoffman SL; Murphy SC
Vaccine; 2023 Aug; 41(38):5494-5498. PubMed ID: 37563050
[TBL] [Abstract][Full Text] [Related]
20. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
